Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kala Bio Inc
(NQ:
KALA
)
5.850
-0.040 (-0.68%)
Streaming Delayed Price
Updated: 3:24 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Kala Bio Inc
< Previous
1
2
Next >
KALA BIO to Present at H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 08, 2024
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 06, 2024
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO Announces $12,500,000 Private Placement
June 27, 2024
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO to Present at Jefferies Global Healthcare Conference
May 29, 2024
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 14, 2024
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 29, 2024
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
February 26, 2024
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 19, 2024
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 20, 2023
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 04, 2023
From
KALA BIO, Inc.
Via
GlobeNewswire
KALA BIO to Participate in Upcoming Investor Conferences in August
August 02, 2023
From
KALA BIO, Inc.
Via
GlobeNewswire
Kala Pharmaceuticals Announces Name Change to KALA BIO
August 02, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 19, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 23, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 02, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 09, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED
April 28, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect
April 12, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor
March 29, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED
March 27, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 08, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 03, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Here’s Why Sotera Health Company Stock Just Doubled in a Day
January 11, 2023
Sotera Health Company (NASDAQ: SHC) is a leading global provider of mission-critical sterilization solutions, lab testing, and advisory services.
Via
MarketBeat
Topics
Emissions
Initial Public Offering
Exposures
Securities Market
Kala Pharmaceuticals Up 400% In The Past Month, What's Next ?
January 10, 2023
Kala pharmaceuticals underwent a massive rally over the past few days, and by all indications, the stock price is now headed toward a bottom.
Via
MarketBeat
Exposures
Product Safety
Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030
December 30, 2022
EQNX::TICKER_START (NASDAQ:SILO),(NASDAQ:BXRX),(NASDAQ:HOTH),(NASDAQ:KALA),(NASDAQ:NUWE) EQNX::TICKER_END
Via
FinancialNewsMedia
Kala Pharmaceuticals (NASDAQ: KALA) Says FDA Accepted its IND Application for KPI-012 and Treatment of PCED
December 28, 2022
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research, development and
Via
Spotlight Growth
Exposures
Product Safety
Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED
December 27, 2022
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.